Advertisement
Advertisement
U.S. Markets open in 54 mins
Advertisement
Advertisement
Advertisement
Advertisement

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.1900+0.1000 (+2.44%)
At close: 4:00PM EDT
4.1600 -0.03 (-0.72%)
Pre-Market: 08:33AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.0900
Open4.0900
Bid4.0800 x 2900
Ask4.2000 x 1100
Day's Range4.0450 - 4.2300
52 Week Range3.7000 - 36.0000
Volume297,383
Avg. Volume4,550,813
Market Cap20.72M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic

    New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturing” Contract with NIHGAINESVILLE, Ga. and SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new development and manufacturing contract by the Nati

  • Business Wire

    Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar™

    BERWYN, Pa., October 06, 2021--Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed an agreement with Sinclair Research, a leading provider of nonclinical research services, to initiate preclinical studies of AnQlar™. AnQlar is being developed by Virpax as a daily over-the-counter (OTC) prophylactic product for treatment against SARS and influenza.

  • Business Wire

    Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021

    BERWYN, Pa., October 01, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, today announced that Chairman and CEO Anthony P. Mack will present an overview of Virpax and take part in a fireside chat moderated by Noble Capital Markets senior equity research analyst, Gregory Aurand at the Pain Management Virtual Investor Forum on Thursday, October 7, 202

Advertisement
Advertisement